RetaMaps

Tri-Valley Clinic

Tri-Valley Clinic · 680 MOWRY AVE · Fremont, CA 94536

5.0· 21 Google reviews

Listing updated October 2, 2026

Quick facts

Address
680 MOWRY AVE, Fremont, CA 94536
Hours (per its website)
Mon,Tue,Wed,Thu,Fri 09:30-17:30
Telehealth
Yes
FDA-approved GLP-1 medications listed
None listed on its website
Accepting new patients (per website)
Yes
Google rating
★5.0 from 21 reviews
Patient sentiment
100% positive, 0% negative (21 reviews analyzed)
Most praised
Friendly, helpful staff (11 reviews)
Most common complaint
None recurring
Social profiles
Instagram
Retatrutide
Not yet available anywhere — investigational, not FDA-approved
Listing last updated
October 2, 2026
Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • Medically supervised weight loss

About this practice

Tri-Valley Clinic is a telehealth psychiatry practice in Fremont, California, with a page describing a GLP-1 weight-loss program. Its website introduces Dr. Shabeg Gondara, MD, as its president, a physician specializing in psychiatry, and offers booking with Dr. Japsharan Gill, MD; care is delivered by secure video to patients anywhere in California, and the weight program begins with a medical evaluation to decide whether GLP-1 therapy is appropriate. On Google it has a 5.0-star rating across 21 reviews, all from 2026, and reviewers most often mention the staff, with 3 each mentioning knowledge, a caring approach and scheduling.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsYes
Cash pay accepted—
Accepts insurance — per practice website—
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 5.0
Google rating · 21 reviews
21
reviews in the past year (avg ★ 5.0)

Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-18. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★5.0 across 21 Google reviews. Of the 21 reviews we analyzed, 21 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).

What patients like

  • Friendly, helpful staff11 reviews
  • Knowledgeable, professional providers3 reviews
  • Feeling listened to3 reviews
  • Easy scheduling and communication3 reviews

Common complaints

No negative reviews among those we analyzed.

5★
21
4★
0
3★
0
2★
0
1★
0

Most recent Google reviews

Dlg G.★★★★★2026-08-27

The doctors here are AWESOME. And the front desk staff is a wonderful person!!!

Qinwu X.★★★★★2026-08-26

I met Dr. Gondara, he is very professional and silled and sympathic, the front desk is very friendly. I highly recommended!

Consuelo B.★★★★★2026-08-12

Our first visit with Dr Gill was great. My 4 clients were so pleased and happy to talk with the doctor. Veronica at your front office was pleasant and friendly, my clients feel at eased and comfortable. We look forward to a long patient/doctor relationship.

Ken G.★★★★★2026-07-24

Very attentive, Non judgmental and very relaxed atmosphere

Antonisha B.★★★★★2026-07-04

This place is amazing and the people who works here are so welcoming.

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Nearby providers in Fremont

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs